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1. Introduction  
Contestations over the regulatory trajectory that developing countries should take to 
embrace the benefits of biotechnology1 have been debated widely. Predominant debates in 
the global arena have focussed on two competing regulatory approaches namely; the more 
permissive approach of the United States (US) that presents biotechnology as posing no risk 
to the environment or human health unless proven otherwise through scientific risk 
evaluation and the more restrictive approach of European Union (EU) that imposes 
precautionary restrictions on use of products of biotechnology even when scientific 
knowledge about risks is uncertain. There is now a wide body of literature looking at trade 
conflicts brought about by these divergent regulatory policies leading to regulatory 
polarization (Paarlberg, 2001, 2008; Bernauer and Aerni, 2007; Bernauer, 2005; Falkner, 2007; 
Murphy and Levidow, 2006). Arguably, these polarised debates only expose the political 
dynamics of biotechnology from a very narrow view, primarily trade imperatives (Clapp, 
2006). Some analysts departing from what they perceive to be a narrow approach to this 
subject have attempted to explain the bumpy path to biotechnology deployment and 
regulation in developing economies that exhibit different characteristics. Millstone and van 
Zwanenberg (2003) for instance looking at GM policies in the South have shown that the 
scientific conflicts embedded in GM safety compel countries to pursue divergent regulatory 
choices. Research has also shown that local context dictates technological dynamics and 
                                                                 
1 Here I use the term biotechnology to mean the manipulation of living organisms to produce goods and 
services useful to human. I make distinction between traditional (or conventional) and modern 
biotechnologies. The traditional approach allows the development of new products (such as seed 
varieties) by the process of selection from genetic material already present within a species, while the 
modern (transgenic) approach develops products (such as seed varieties) through insertion of genetic 
material from different species into a host plant. These products are popularly known as Genetically 
Modified Organisms (GMOs).   
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should be given a place in biotechnology development and regulation (van Zwanenberg et 
al., 2008). Falkner and Gupta (2009) have also noted that despite the EU-US international 
regulatory conflicts, developing countries are responding to related pressures in different 
and unique ways.  
Important for this paper is the dynamics brought about by regulatory pressures and what 
this means for knowledge use towards productive debates that could lead to pro-poor 
biotechnology development. In view of this, there is need to re-orient the discussions 
around how actors in the respective value chains ought to respond to regulatory demands 
brought about by biotechnology, and how this impacts knowledge production dynamics. 
The paper argues that biotechnology development will only contribute to economic 
development if knowledge (regulatory, social and scientific knowledge), emanating from 
different knowledge nodes is allowed to converge to a point where it can consequently 
inform productive innovation policy processes. This argument is based on the 
understanding that requisite innovation capacities need to be built in order for actors to use 
the resources at their disposal towards behavioural change for biotechnology regulation 
(Hall, 2005). Knowledge is one of the resources and how it is applied is crucial for 
biotechnology innovation process or trajectory.   
This paper relooks at knowledge production dynamics through an empirical account that 
documents the biotechnology regulatory trajectory in Kenya. The analytical context for the 
paper is backed by the political nature under which biotechnology development and 
biosafety regulation have co-evolved for almost two decades (Harsh, 2005; Sander, 2007; 
Kingiri and Ayele, 2009, Kingiri, 2010, 2011a,b). Analysis drawn from these papers suggests 
that scientific knowledge predominantly directs biotechnology development and regulation 
(cf Kingiri, 2010). In addition, the fragmented nature of actors’ infrastructure and their belief 
systems derail the knowledge convergence efforts (Kingiri, 2011a). Although this process 
lacked legal direction in terms of policy (Biotechnology policy and Biosafety Act were only 
approved in 2006 and 2009 respectively), the paper suggests that lessons learnt in the 
Kenya’s regulatory process should move the country biotechnology sector to a higher level 
towards putting the research products which have been in the pipeline to use. The objective 
of the paper therefore is to explore and understand how knowledge convergence can be 
attained towards moving biotechnology science forward towards innovation. 
The paper is structured as follows. Political scenario under which biotechnology regulation 
occurs is discussed first. This is followed by an analytical context under which this paper is 
situated. Next, the paper illuminates the dynamics associated with biotechnology regulation 
using Kenya as an example. Lastly, the paper discusses the emerging dynamics associated 
with regulation and role of knowledge actors. It then concludes by drawing lessons that 
might inform a productive regulatory process towards knowledge convergence.  
2. Political nature of biotechnology regulation: An overview 
It is now understood that agricultural production constraints like pests and diseases have 
been perpetuating the cycle of food insecurity and poverty in sub-Saharan Africa. The 
questions that many have been asking relate to whether biotechnology can be exploited as a 
possible solution to these and other production constraints. Proponents are optimistic about 
this while opponents are pessimistic citing safety concerns around human health and 
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environment. Answers to these and related questions provide a more complex and charged 
debate about biotechnology development and regulation.  
Despite the undisputed consensus about biotechnology as a tool for agricultural 
development in poor economies (FAO, 2004), political polarization on GMOs has been 
increasing. The participation of many interested stakeholders in charting a supposedly 
sustainable regulatory pathway has confounded the process due to the value based nature 
of divergent perspectives (Paarlberg and Pray, 2007; Leach et al., 2007). It has been noted 
that policy processes embraced in advanced economies particularly EU and USA has 
significantly shaped public opinion and regulation in most African countries (Newell, 2003). 
EU for instance has been associated with advocacy groups opposing biotechnology 
introduction even in regions where food security challenges persist (Herring, 2010; 
Paarlberg, 2001, 2008). Other analysts have further explored the problem more broadly and 
have added that a more holistic approach to biotechnology debate is needed to embrace the 
context that varies with regions, localities and social preferences (van Zwanenberg et al., 
2008; Glover, 2010).    
This paper is in line with holistic view of biotechnology regulation that take cognisance of 
the context specific nature of domestic knowledge dynamics prompted by biotechnology. 
This includes environmental and social economic context, political and cultural context in 
relation to how decision processes are pursued to promote legitimacy and transparency 
among others (Glover, 2010). Arguably, these factors shape knowledge production 
dynamics giving a context to the analysis.  
3. Setting the scene: Conceptual and analytical context 
Building on some of the studies on biotechnology governance in Kenya alluded to 
elsewhere; this section calls attention to the importance of the various aspects of 
technological, regulatory and social local contexts in which the knowledge actors (including 
the organisations involved) and regulatory process are embedded. It seeks to provide the 
analytical context for the paper as well as situate the multiple actors engaged in 
biotechnology research and development (R & D) for the last two decades within the 
process of regulation implementation. By doing this, the paper exposes the motivations and 
opportunities for actors in their engagement with biosafety regulatory process and 
formulation of regulatory instruments, and the institutional challenges and strengths related 
to modern biotechnology governance.  
The paper seeks to analyse how biotechnology regulation (which includes instituting a 
biosafety regulatory system for management of biotechnology) may have affected efforts to 
bring about a knowledge convergence in biotechnology regulation. Kenya was selected 
backed by the rich political context that prevailed during the establishment of a regulatory 
system for management of biotechnology Research & Development (R & D). 
3.1 Research context and methodology 
Kenya presents an excellent case to investigate knowledge management associated with 
modern biotechnology in terms of regulatory policy environment and context. This is 
because the initiation of biotechnology R & D activities that commenced in 1990’s paralleled 
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the establishment of the requisite regulatory process providing an exemplary context to 
investigate the dynamics around knowledge production with both technological and 
regulatory orientations. This parallel process engaged communities in research, policy and 
public arenas in an iterative manner bringing about interesting biotechnology and 
institutional innovations. Secondly, policy initiatives like the strategy for revitalising 
agriculture (RoK, 2005) and the Vision 2030 embrace an integrated approach to innovation 
towards economic development.   
The context described above  created a conducive environment to undertake qualitative in-
depth semi-structured interviews with over 50 individual knowledge actors who had (or 
claimed to have) a stake in decisions pertaining to biotechnology as researchers, policy 
makers, employees of nongovernmental organisations (NGOs) and members of the public 
(mainly consumers and farmers). The research period was between 2006 and 2011. This was 
complemented by observations carried out during different scientific and public workshops 
in biosafety and biotechnology held during this period, and analysis of relevant secondary 
documents. Interviewees’ points of engagement in the regulatory activities and decision 
processes are seen in the context of effort to provide knowledge (e.g. information, expertise 
and other resources) to influence policy outcomes. Consequently, the data analysis captured 
the different ways knowledge is used in the regulatory processes and what factors come into 
play. 
Unless otherwise stated, codes are used to report all information cited in this paper in order 
to guarantee anonymity of some of the interviewees as requested. For instance, NGOco-NS4 
refers to a non scientist interviewee from a civil society organisation. 
3.2 An overview of Kenya’s biotechnology development and regulation  
3.2.1 Milestones in Kenya’s biotechnology sector 
Modern biotechnology has revolutionised many sectors including agriculture and embraces 
a wide range of applications including tissue culture, markers assisted selection and genetic 
engineering (GE) also referred elsewhere in this paper as modern biotechnology. All these 
are being applied in Kenya, but the latter is the focus of this paper. Just like many African 
countries, GE is relatively new, but GE products have been handled indirectly through trade 
in form of food aid (Kagundu, 2008).  
Agricultural R&D has long been recognised as central to knowledge creation, technology 
development and innovation. During the pre-independence period, the R & D agenda was 
set by the British colonial government, which recognised the importance of Science and 
Technology (S & T) in agricultural production (Ochieng, 2007). It is not until early 1990’s 
that biotechnology innovations in form of tissue culture received considerable attention 
(Wambugu, 2001). Actual work involving advanced GE commenced in 1991 when Kenyan 
scientists went to USA and in collaboration with scientists there, engineered a virus resistant 
sweet potato (Odame et al., 2003).  Thereafter in 1998, the transformed plants required 
regulatory approval for this research to continue in Kenya. However, actual process of 
regulatory process and implementation had commenced prior to 1998.  
To date, over six GE R & D initiatives have been evaluated in public institutions in 
conjunction with local and international partners (see Kingiri, 2011a for details). These 
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activities include Bt maize and Bt cotton engineered for resistance to insect pests, cassava for 
resistance to viruses and sorghum for resistance to striga weed. The recombinant rinderpest 
vaccine initiative targeted control of rinderpest disease in cattle and other viruses in small 
ruminants. Other initiatives are in the pipeline for example the sorghum fortified with 
nutrients funded by the Bills and Melinda gates foundation through the Africa Harvest 
Biotechnology Foundation International (see www.africaharvest.org). Since the approval of 
the first transgenic crop- the sweet potato in 1998, no product has reached the farmers and 
the furthest the biotechnology activities have gone towards a product is the (CFTs)2. It is 
hoped that with the establishment of a functional biosafety framework, the situation will 
change. In addition, the food insecurity related issues have prompted the government to 
take drastic policy measures approving importation of GM maize to avert a food crisis in the 
country (Daily Nation, 2011).  
3.2.2 Biosafety regulatory mechanism  
Biosafety encompasses the regulatory mechanisms that the government has put in place for 
the governance of GE activities. Article (8g) of the Convention on Biological Biodiversity 
(CBD, 2000) and Article (16) of the Cartagena Protocol provide for establishment of 
appropriate mechanisms to regulate, manage and control risks associated with Living 
Modified Organisms (LMOs). The protocol emphasises on risk assessment (RA) and risk 
management, and provides guidelines to achieve this (Annex III). There are several ways in 
which risk identified during RA can be managed, e.g. confinement, restricted use, provision 
of guidance, technical advice and record keeping (Halsey, 2006). 
At the early stages of biotechnology research activities, Kenya opted to use the existing 
infrastructure, the Science & Technology Act (RoK, 1980) to institute regulatory mechanisms 
through the drafting and adoption of the Regulations and Guidelines for Biosafety in 
Biotechnology in Kenya (RoK, 1998). There were concerns that these regulations came long 
before the biotechnology policy and have not been legally binding as required by the law. In 
an effort to legalise the regulations as well as the biotechnology activities, the National 
Biotechnology Development Policy was drafted and later approved in 2006 (RoK, 2006). This 
was followed by Biosafety Act, 2009 (RoK, 2009). Kenya signed and ratified the Cartagena 
Protocol in May 2000 and January 2002 respectively. This further obligated the government 
to put up regulatory structures to operationalise it. This Biosafety Act therefore primarily 
seeks to operationalise the Protocol. The controversial developments surrounding its 
formulation over the years are at the centre of this paper. Kingiri (2011a) captures some of 
the main developments, revealing the dynamics that include the engaged different actors 
and the nature of engagement between 2002 and 2009. Within this period, various versions 
of the biosafety bill were drafted and discussed before the final version (RoK, 2009) was 
approved to become an Act in Feb. 2009. Meanwhile, regulations to be appended to the Act 
were drafted under the Program for Biosafety Systems (PBS) support and recently became 
operational from July 2011 after signing by the Minister for Higher Education, Science and 
Technology.  
                                                                 
2 This is a field trial of GM plants not approved for general release in which measures for reproductive 
isolation and material confinement are enforced in order to confine the experimental plant material and 
genes to the trial site (Halsey, 2006:4). 
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Previously, all the involved government actors and other nongovernmental players involved 
in biotechnology governance were brought together under the National Biosafety 
Committee (NBC) coordinated by the National Council for Science and Technology (NCST). 
NBC acted as a boundary organisation overseeing the management of biotechnology 
research through regulation. This role has since been taken over by the National Biosafety 
Authority (NBA) formed under the provision of the Biosafety Act.   
3.2.3 Theoretical framework 
To analytically situate the discussion in sound theoretical debates, this paper draws upon 
insights from the integrated knowledge management literature. Scholars try to explain the 
changing role of science in policy deliberations and the changing integrated knowledge 
production architecture prompted by new technological developments (Gibbons et al., 1994; 
World Bank, 2006). In the case of biotechnologies, this brings about governance challenges 
linked to biosafety regulation imposed to promote technological competitiveness and 
encourage public acceptance of these new technologies (Lyall, 2007).  
4. Dynamics associated with biotechnology regulation: An empirical 
exploration of Kenya’s case 
In this section, practical reasons why and how stakeholders got entangled in Kenya’s 
regulatory process is explored and the kind of reactions this generated. This helps us 
understand the challenges that may hamper a productive regulation towards knowledge 
convergence.   
4.1 Challenges confronting the evolving agricultural R & D and modern biotechnology 
governance terrain 
4.1.1 Contract research 
It is widely argued that biotechnology is a key tool for 21st century sustainable development. 
However, most people agree that this may remain a dream unless certain challenges are 
addressed that include political support through provision of incentives for research and 
regulation (cf Bananuka, 2007). In Kenya, government support for S & T including 
biotechnology R & D has been minimal (Beintema et al., 2003; Odame et al., 2003). The 
dwindling research funds and other policy reforms have encouraged collaborative research, 
technology development and deployment (RoK, 2005; KARI, 2005; RoK, 2007). Although the 
government continues to fund public agricultural research, a significant support comes from 
donor organisations (Beintema, et al., 2003:5). Kenya Agricultural Research Institute (KARI) 
being the major research institute involved in modern biotechnology research (and the only 
one undertaking biotechnology CFTs) has undergone significant restructuring in response 
to these reforms and challenges. These changes have contributed to a rise in contract 
research characterised by increased donor funding (Beintema, et al., 2003:5). For instance all 
the agricultural GM trials are being undertaken through Public Private Partnerships (PPPs) 
arrangement (Ayele et al., 2006).  
A lot has also been documented regarding the tissue culture bananas contract research (cf 
Smith, 2004). However  in the case of modern biotechnology, the nature of contractual 
research is still under-researched and is undergoing changes at unprecedented rate due to 
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the evolving institutional and regulatory contextual issues. What seems to lack is 
information on how actors in the value chain have been responding to the institutional 
changes associated with regulation of biotechnology science. This is crucial for related 
knowledge convergence efforts.  
4.1.2 Biotechnology and biosafety capacity  
According to Bananuka (2007), the need for regulatory capacity evolves alongside an 
operational biotechnology sector, and this has been the case in Kenya. Since the 
biotechnology programme was initiated in early 1990’s, capacity in both modern 
biotechnology techniques and biosafety (human, infrastructural and institutional) has been 
built over the years. For instance, a modern biosafety Level II greenhouse has been put up at 
the KARI biotechnology centre. According to a report prepared for policy makers 
(Handbook for Policy Makers, 2007), the number of scientists trained in biotechnology 
countrywide has gone up, with 45% of those trained being actively engaged in GE work. In 
addition, capacity in regulatory institutions like Kenya Plant Health Inspectorate Service 
(KEPHIS), Kenya Bureau of Standards (KEBS), Department of Veterinary Services (DVS) 
and Department of Public Health (DPH) has been strengthened and as argued in this report, 
these institutions are in a state to oversee the implementation of biosafety regulations. 
Arguably, these rhetorical claims were advanced by GMOs proponents, in their endeavour 
to lobby for the enactment of the bill (Kingiri, 2011a, b). However, these capacity building 
and biopolicy developmental efforts have been collaborative.  Despite these milestones, both 
infrastructural and human capacity remains far from being adequate. This is attributed to 
several factors among them inadequate government support for research discussed above 
and lack of regulatory policy environment to spur development (Wafula et al., 2007), that 
would further encourage and favour capacity building efforts. The increased cross-over of 
trained scientists from public institutes to international organisations locally and abroad has 
also contributed to the unsustainable capacity building efforts, a trend which is prevalent in 
the African region as a whole (Hastings, 2009).  
4.2 Stakeholders’ proactive role in regulatory process 
From the foregoing analysis, it is emerging that various challenges have hampered the 
evolution of the twin processes - biotechnology innovation and regulatory regime. These 
relate to partly the technical and institutional capacities, but this analysis does not address 
an important question related to how the actors (individuals, organisations and related 
links) deal with the analysed challenges. The implications in terms of how challenges are 
dealt with are important in informing the dynamics around knowledge use and regulatory 
decision making processes.    
This section tracks empirically the Kenya’s regulatory trajectory paying attention to the 
involvement of knowledge actors in this process, exposing the tensions that this generated. 
It is important to note that many interviewees desired a regulatory environment that would 
enhance deployment of products of GE science. Biosafety bill was a gateway towards 
achieving that goal. Media reports analysed during field work confirm some activism by the 
scientific and non scientific communities in support or against the biosafety bill. Biosafety 
formulation process as a pertinent step in legalising the regulatory regime engaged the 
scientific community intensely. Scientists collectively educated policy makers and 
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journalists, sensitizing them on GE thus making “a case for biotechnology” as well as 
persuading them to support it (RSIn-GP2, Dec. 2007).  This was however viewed with 
suspicion by some interviewees, who were concerned with what they viewed as 
biotechnology promotional agenda and associated politics. Several documents obtained 
during field work and numerous media reportage by both proponents and opponents 
seemed to confirm this pro-activeness (see Kingiri, 2011a for a detailed empirical account of 
dynamics involved).  
4.2.1 Motivations, opportunities, interests and implications associated with 
biotechnology 
When biotechnology research was initiated in early 1990’s it provided an incentive for 
researchers with many seizing this opportunity to pursue their knowledge and technology 
transfer endeavours. This triggered public reaction with this behaviour being interpreted by 
non scientific communities from the civil societies as unwarranted excitement and hype. To 
moderate the different interests and concerns, amongst stakeholders, the government 
imposed biosafety regulations (RoK, 1998) to guide in subsequent knowledge generation 
endeavours and decision making processes. Regulations were interpreted in different ways 
by different stakeholders (see Kingiri, 2011b for details). Perhaps because of conflicts 
between different motivations and opportunities presented by GE research, and the 
different challenges associated with biosafety regulations and implementation, the 
stakeholders exposed certain varying behavioural practices. This generated varying 
reactions as reported in the subsequent sections.  
4.2.2 Scientists credibility and transparency questioned 
The conduct of GE trials was perceived to require a substantial level of credibility on the 
part of scientists due to sensitivity of GE technology. However, research scientists were 
perceived by a number of interviewees to be untrustworthy and dishonest. Perhaps 
credibility is one aspect that regulations should be promoting, prompting regulators to 
emphasise appropriate monitoring of research trials and scientists: “scientist…will do things 
that you cannot believe it is possible.” (RSPu-PS7, Nov. 2008). Credibility was however found to 
be constrained by institutional obligations and compromises that both scientists in policy 
and practice were forced to make. The interim regulations prior to the Biosafety Act were 
unclear about how credibility as an ethical practice is linked to compliance and monitoring. 
However, the Biosafety Act provides for intensive monitoring through designated biosafety 
experts (Articles 43 & 45). 
4.2.3 Attitude towards regulations and regulators 
Many interviewees in policy arena including regulators described scientists as having a 
negative attitude towards regulations. The reasons behind this negative attitude were 
attributed to conflicting motivations like research interests discussed previously, making 
scientists view regulations as “hindrance to science” (LABp-NS8, Jan. 2008). Others explained 
that scientists find it difficult to adjust from their normative basic research behaviour to a 
supposedly demanding research practice like the one demanded by GE research. The 
attitude of researchers towards regulators and vice versa promoted suspicions and 
misunderstandings amongst them, constraining effective regulatory practice.  
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4.2.4 Poor public communication and biased reporting 
This section reports on practice of scientists related to how they disseminate research 
information emanating from biotechnology research trials. The regulatory instruments prior 
to the Biosafety Act and the Act itself are implicit about how this reporting process should 
be managed. They however emphasise on transparency that should promote public trust. 
RoK (1998) in particular recommends “openness” to “safeguard public interest” through 
transparent handling of information and adhering to regulations (executive summary). In 
RoK (2009), NBA is wholly responsible for information handling and management 
including consequent public awareness. A register will also be maintained as a repository 
for biosafety information.  It is however unclear how interested parties should access it.  
Accounts of interviewees suggested that scientists have poor public communication skills on 
biotechnology matters. In addition, when they communicate (as demanded by the sensitive 
nature of this technology), there are weaknesses that are revealed through the reports and 
the communication strategies they adopt. However, many interviewees were in agreement 
that scientists have a very important role to play in communicating scientific and technical 
facts to the public about their GE work. Some perceived this as the only way of 
demystifying the prevailing negative publicity around GE technology. There were however 
perceived weaknesses and challenges in the articulation of this role which are explored next.  
4.2.4.1 Communicating science versus public understanding of science  
Some interviewees claimed that research scientists use “scientific jargon” that need to be 
“toned down” for lay people to understand. The use of technical and scientific language was 
perceived to be an indicator of poor communication skills that purportedly differentiates 
pro-GE scientists from anti-GE activists. This discussion seems to point out that scientists 
have not come to the level of the non scientists or the public when communicating technical 
aspects of GE research. This analysis does not however expose the reasons behind this 
seemingly uncomfortable behaviour and repercussions.  
4.2.4.2 Public communication constrained by fear of misinterpretation  
Scientists argued that they deliberately avoid communicating scientific findings to the 
public because of fear of misinterpretation, propaganda and potential negative impact this 
may have, for instance on their careers and research reputation. Fear of propaganda was 
associated with activists, who some claimed unjustifiably fight biotechnology impacting on 
scientists’ reporting behaviour: 
“So [research scientists] have avoided bringing negative stories and even when they see them they 
remove them and instead keep quiet. Experience has shown that, any negative you bring will be used 
against you. So we have to continue in the way I think we are at least less risky.” (TAR-NSS1, 
researcher & technology advocacy, international NGO, Feb. 2008) 
This has implications as many scientists asserted. The fear of reporting non-factual and 
unverified or unconfirmed findings constrain effective and timely reporting, leaving room 
for misinterpretation by counter groups. Arguably, scientists are held back from freely 
sharing their findings with the public for fear of repercussions associated with 
misinterpretations. This has implications for practice on the part of the scientists in 
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4.2.4.3 Communicating the positives and transparency 
Majority of scientists admitted that when scientists communicate about GE science, it is 
basically the positive and promotional information that highlights benefits more than risks. 
Misinterpretation was affecting the way scientists communicate, compelling them to talk 
more of tangible benefits and less on unverified or “unknown” risks. Several non scientist 
interviewees corroborated the “biased reporting” linked to provision of information inclined 
more to successes:  
“In Kenya, all we are hearing are the positive aspects. We know that no technology in this world is 
without risks.  So why is the potential risk side [of GE technology] silent? That in itself sends alarm 
bells to us [civil society].” (NGOf-NS1, farmers’ rights advocacy, civil society, Nov. 2007) 
Defending this practice, some researchers argued that, the nature of biological science 
training encourages them to pursue only facts, compelling them to withhold information 
that cannot be validated. This was discussed in connection with confidence and easiness in 
reporting facts as opposed to unverifiable information like cases of uncertainty. They further 
argued that reporting on GE risks may cause panic among the public if negative non-
validated aspects related to scientific “process” are highlighted. However other interviewees 
claimed that, scientists withholding of some information was linked to “a normative rigid 
research practice” that compels them to vet what they report (ATp-PS3, Nov. 2007). This 
analysis seems to portray scientists as self centred, and tends to put to doubt their previous 
claims of fear of misinterpretation. Questionably, there is a disconnect between constrained 
communication and the unbalanced information consequently disseminated. 
4.2.4.4 Unreliable & biased information and multiple obligations  
Exogenous pressures were perceived by a number of scientists and most civil society 
interviewees to be limiting the reporting freedom of researchers, prompting them to 
produce what was referred to as “biased” and “unreliable” information, presumably 
manipulated to suit certain interests.  Many felt that, reports emanating from research trials 
were unreliable because of the partnerships environment under which the trials are 
undertaken. This was perceived to be prompting reporting that favoured multiple 
obligations commensurate with different interests.  This created tension amongst the civil 
societies: “it is difficult to say per se that in the current [donor] context the information from those 
researchers would be fully reliable” (NGOco-NS4, consumers’ network, Jan. 2008).  
The preceding analysis suggests that certain technical and non technical factors largely 
influence the behavioural practice exhibited by scientists in knowledge production 
endeavours linked to biotechnology regulation. Some factors are associated with 
opportunities presented by GE science, while others are linked to challenges that confront 
actors including scientists as they engage in biotechnology research and regulatory process.  
4.2.5 Technical experts and conflicts of interest 
National efforts to establish a legally binding regulatory regime in compliance with 
Cartagena Protocol engaged stakeholders in various ways. One of the roles of the NBC 
according to RoK (1998) was to draw policies and procedures to govern biotechnology. In 
this regard, this gave NBC the legal powers to spearhead the policy-making process. 
However, NBC coordination role in the biosafety bill formulation process was perceived to 
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be blurred by the activism of other actors, a view shared by both scientists and non 
scientists. Arguably, the scientists and their allies became the main drivers of the bill 
formulation process:  
“The main players were the biotechnology industry, and the scientists make much of the industry. 
The whole process was supposed to be an initiative of the government but the interest was with people 
from the biotechnology industry than what we would call the broader section of Kenyan society.” (JO-
NS6, journalist, local daily, Apr. 2008) 
NBC was also largely made up of scientists representing different organisations with two 
representatives from the civil society. This being the case, it can be concluded that scientists 
and their affiliated institutions played vital roles as technical experts (see Kingiri, 2010). This 
role is however threatened by perceived motivations and interests likely to bring about 
conflicts of interest.  It was a concern of non-scientists from the civil society that technical 
information used in risk assessments (RA) and consequent decision making pertaining to 
GE trials was solicited by scientists from technology developers who are interested parties.   
The relationships established around the regulatory process in the Kenyan context were 
mutual in that the participating players expected to benefit. Scientists and the government 
were for instance receiving financial support from non state actors and donors. These 
relationships and partnerships were perceived by many interviewees to have positively 
enhanced the regulatory process. Further, some interviewees were in agreement that the 
government has inadequate capacity to support the regulatory process, so these other 
supporting parties were filling in that gap. From these accounts, resources and in particular 
financial support was a key incentive cementing these relationships.  
4.3 The never ending controversy 
The Biosafety Act (2009) approved in Feb 2009 may be seen as a victory for agro 
biotechnology development towards benefiting the poor. The formation of an 
administrative entity, the NBA to legally manage biosafety controversies under the 
provision of this Act may also be seen as a plus towards development endeavours. 
However, the broader food security issues as well as socio economic and political 
environment mask smooth biotechnology development and regulation. On 14th February 
2011, the Kenyan cabinet made a political pronouncement that approved immediate 
importation of GM maize to avert a looming food crisis. This development received 
considerable media reportage which subsequently generated wide public protests led by 
civil society (see Opiyo, 2011; Omondi, 2011; Kinuthia, 2011). The proponents who include 
scientists did not see anything wrong with the importation citing scientific evidence that has 
shown GM products to be safe for human consumption. The opponents expressed 
scepticism citing unconfirmed risks posed by these products to human health.  This 
controversy suggests that the debate surrounding biotechnology clearly continues to remain 
polarised making it harder for the public to endorse biotechnology products. This is a major 
drawback to science advancement as well as a threat to its longstanding authority in 
providing solutions to societal problems.     
5. Discussion and conclusion 
The foregoing empirical exploration of Kenya’s regulatory process exposes a controversial 
engagement in knowledge production dynamics. This is in part linked to weak governance 
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structures in terms of both biotechnology delivery and related regulatory mechanisms. This 
has implications for productive knowledge convergence efforts. Firstly, in relation to who 
should be involved as stakeholders in the regulatory process and how they should be 
engaged, the Kenya’s case presents major participation and transparency challenges. The 
regulatory process although enlisting participation of both technical and non technical 
experts sidelined the public expertise (see also Kingiri, 2010). This may imply that expertise 
that may bring on board socio, economic and cultural contexts of Kenya’s broader 
agricultural terrain could have been ignored in decision making processes. For instance, the 
public private partnerships that are currently evident in Kenyan biotechnology initiatives 
are largely triggered by technical and financial constraints (Intellectual Property Rights-
IPRs, infrastructure, funding, individual scientists interests etc) as opposed to the needs and 
production constraints that can benefit farmers. Secondly, the resources (including 
knowledge and information shared and disseminated amongst players, regulatory 
instruments, legal and administrative structures, media as avenue for information 
dissemination and experts) that purportedly steered the regulatory dynamics were not 
devoid of conflicts of interests and influence. This has implications for productive 
knowledge convergence efforts as it generates suspicion, luck of trust and perhaps potential 
rejection of science.  
In a complex science policy terrain like biotechnology regulation, multiple contexts may 
work for or against the intended innovation and public policy. Thus, the following question 
posed by Haas, (1992:1) is very valid. Can policy makers or scientists themselves “identify 
national interests and behave independently of pressures of social groups they nominally represent?” 
He argues that, actors can learn new patterns of reasoning informed by a wider stakeholder 
needs and interests. The general argument advanced here is that technical experts that 
include scientists can genuinely play their part to influence positive change in policy-
making through appropriate use of knowledge and information (Haas, 1992:3). The 
scientific community has a major role to play in this because they understand the 
complexities and uncertainties associated with biotechnology better than the non-scientists 
and policy makers (Bradshaw and Borchers, 2000). In addition, inclusion of a wide range of 
expertise that encompasses non-technical professionals is a positive way to democratise the 
regulatory process towards a socially robust knowledge production infrastructure 
(Nowotny, 2003; Nowotny et al., 2001, 2003).  
The behavioural practice exhibited by Kenyan scientific experts in generation and handling 
of biosafety related information could be a concern for a productive knowledge convergence 
that is intended to promote biotechnology development and adoption. To promote 
credibility and transparency and consequently enhance trust associated with biotechnology; 
this paper further suggests a change of attitude of actors towards a socially responsible 
process. The scientific community and policy makers and those groups that claim to 
represent the farmers and public must be honest with no hidden agenda (Ammann and 
Ammann, 2004). In addition, reflexivity should be encouraged. As a value based practice, 
reflexivity is the process by which individuals involved in knowledge production try to 
operate from the standpoint of all experts involved (Gibbons et al., 1994). For the purpose of 
enhancing knowledge convergence in biotechnology development, expertise from different 
stakeholders should be considered in biosafety regulation and other decision making 
processes.   
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6. Lessons towards knowledge convergence 
This section looks at insights that this paper can draw upon from almost two decades of 
Kenya’s biotechnology and regulatory regime co-evolution in terms of practice. Three 
distinct aspects are key in putting the lessons discussed here into context: 
Dynamism: Biotechnology innovation is advancing at an unprecedented pace, perhaps 
faster than the capacities of actors and institutions to adjust in order to accommodate the 
requisite changes needed to foster innovation and responsive engagement of stakeholders, 
including regulation (Tait et al., 2006:379). This has called for new styles of governance that 
urge for participative decision making processes that consider all stakeholders’ interests and 
values (Lyall and Tait, 2005).   
Multifaceted: Both biotechnology innovation and the embedded regulatory process involve 
many actors with each process being multifaceted. Consequently, the accompanying 
practices that actors chose to adopt or pursue are perceived to be problematic. According to 
Murphy and Chataway (2005), this may be attributed to influence of different policy 
cultures at the global level (e.g. EU versus US) and regional level (e.g. African Union). In the 
case of Sub Saharan Africa, this is also connected to influence of policy cultures at national 
levels (Mugwagwa, 2008).  
Complexities related to shifting regulatory practice: The entire biotechnology and 
regulation revolution involves complex trade related and institutional dynamics (Fukuda-
Parr, 2006) which inevitably impacts behaviour of actors like scientists. In Kenya, the 
behavioural shifts are sometimes encouraged by the inadequate and specialised 
biotechnology-biosafety knowledge capacities needed to move the regulatory process 
forward. This may not be construed to be a bad thing because within a dynamic and 
functional system like biotechnology, this may promote cumulative knowledge and 
learning. However, how learning and knowledge are managed is important for practice.  
Considering these dynamics, a number of lessons can be drawn in relation to knowledge use 
and policy making as explored next. 
6.1 Harnessing the positive aspects and dealing with the negative aspects  
We cannot rule out the important learning that has taken place in the evolving Kenya’s 
biotechnology regulatory system for almost two decades both at the institutional and 
individual levels, much of which constitute tacit knowledge. The government has to look for 
ways of using this accumulated knowledge. One way it can do this is to compile a list of 
experts who have been involved, and perhaps include and consider them as official experts. 
They would then be called upon from time to time in biotechnology and biosafety 
awareness campaigns and capacity building efforts targeting the wider stakeholder 
communities. In addition to sensitising people about specific technical subjects, they would 
also be requested to talk about their experiences in biosafety regulatory process, providing a 
platform for meaningful deliberations that can bring about knowledge convergence 
promoting pro-poor and pro-biotechnology innovation agenda.  
It is possible that the regulatory dynamics discussed in Section 5above may have a negative 
impact on future biotechnology deployment and adoption. For instance, the scientific 
community’s active participation in the regulatory process may have resulted into more of 
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technical and scientific knowledge informing the policy deliberations. This may have 
ignored some other relevant knowledge which may enhance convergence efforts. These 
possible negative aspects cannot be ignored and have to be factored into future decision-
making processes. How can this be done?  
• The government has a major role to play by adopting a governance approach to public 
policy processes through weighing and analysing the types of knowledge that inform 
the process. The objective would be to ensure that socially desirable knowledge informs 
the final policy outcome (Nowotny et al., 2001).  
• The government needs to build and sustain technical capacities thereby have a wide 
pool of experts in which to draw expertise from. It should also spread its wings to other 
academic and non academic institutions to solicit expertise not only for regulatory 
instruments, but also for overall risk assessment and environmental safety reviews.  
6.2 Reconceptualising policies formulation process 
In addition to the above lessons, the significant shift in behavioural practice associated with 
knowledge actors demonstrated empirically in the Kenyan case that accompany the 
biotechnology and biosafety revolution lead to a compelling urge to reconsider how policy 
and regulatory formulation processes are conceptualised and articulated. Regulatory practice, 
if it is to achieve greater effect in reconciling the governance agenda of modern biotechnology 
on the one hand, and role of actors in providing evidence-based expertise into the process; it 
must factor into the process this inevitable change in practice. This is not to denounce the 
economic and institutional factors in which this shift is embodied, but rather to suggest that 
this becomes an additional consideration in policy processes. Since this shift is exhibited by 
actors spread out in different institutions (academic, policy, NGOs, public), effective policy 
and regulatory processes must first acknowledge its potential to influence policy directions. 
Consequently, strategies should be devised that encourage a reflexive and responsive 
behaviour (Lyall, et al., 2009: 261). This may enrich how policies are implemented considering 
that cultural practices in biotechnology are linked to values and interests (Laurie et al., 2009).  
In conclusion, the paper appeals to the policy, public and scientific communities to adopt a 
reflexive approach to biotechnology development and regulation in order to enhance 
convergence of knowledge for sustainable development.    
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